MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To guage numerous intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal trial objectives were to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though one of several... https://lennyv009ite3.wikirecognition.com/user